CompletedNCT04315792
Endoxifen for People With Type I Bipolarity: Safety Study
About this title
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Read the official source — NCT04315792Researchers compared Endoxifen and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared Endoxifen and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- MiamiSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 3, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 124
- Sponsor
- Jina Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04315792
- Official title
Show the full official title
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Miami
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Endoxifen and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I.
Who is behind this study?
The study sponsor is Jina Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Endoxifen and Placebo oral tablet.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
